International Journal of Cancer Management

Published by: Kowsar

The Relationship Between Risk Factors and Survival in Adult Acute Lymphoblastic Leukemia

Abolghasem Allahyari 1 , Seyed-Mehdi Hashemi 2 , Fahimeh Nazemian 3 , Mohammad Karimi 1 , Mohammad-Reza Kazemi 1 and Masoud Sadeghi 4 , *
Authors Information
1 Department of Hematology and Medical Oncology, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 Department of Hematology and Medical Oncology, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Cancer Research Center, Kermanshah University of Medical Sciences, Kermanshah, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: August 2016, 9 (4); e5045
  • Published Online: August 10, 2016
  • Article Type: Research Article
  • Received: December 14, 2015
  • Revised: February 6, 2016
  • Accepted: August 6, 2016
  • DOI: 10.17795/ijcp-5045

To Cite: Allahyari A, Hashemi S, Nazemian F, Karimi M, Kazemi M, et al. The Relationship Between Risk Factors and Survival in Adult Acute Lymphoblastic Leukemia, Int J Cancer Manag. 2016 ; 9(4):e5045. doi: 10.17795/ijcp-5045.

Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Levitt L, Lin R. Biology and treatment of adult acute lymphoblastic leukemia. West J Med. 1996; 164(2): 143-55[PubMed]
  • 2. Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013; 50(3): 185-96[DOI][PubMed]
  • 3. Pulte D, Jansen L, Gondos A, Katalinic A, Barnes B, Ressing M, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One. 2014; 9(1)[DOI][PubMed]
  • 4. Ahmed MB, Shehata HH, Moussa M, Ibrahim TM. Prognostic significance of survivin and tumor necrosis factor-alpha in adult acute lymphoblastic leukemia. Clin Biochem. 2012; 45(1-2): 112-6[DOI][PubMed]
  • 5. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009; 46(1): 64-75[DOI][PubMed]
  • 6. Ibrahim A, Ali A, Mohammed MM. Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols. Adv Hematol. 2014; 2014: 697675[DOI][PubMed]
  • 7. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010; 150(4): 389-405[DOI][PubMed]
  • 8. Rowe JM. Getting to the root of (it) ALL. Blood. 2010; 115(18): 3649-50[DOI][PubMed]
  • 9. Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013; 98(11): 1702-10[DOI][PubMed]
  • 10. Larson RA. Acute lymphoblastic leukemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program. 2005; : 131-6[DOI][PubMed]
  • 11. Wiernik PH, Dutcher JP, Paietta E, Gucalp R, Markus S, Weinberg V, et al. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen. Leukemia. 1993; 7(8): 1236-41[PubMed]
  • 12. Park SR, Kim JH, Kim DY, Lee S, Lee SY, Choi IS, et al. Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors. Korean J Intern Med. 2003; 18(1): 21-8[PubMed]
  • 13. Mashhadi MA, Koushyar MM, Mohammadi M. Outcome of adult acute lymphoblastic leukemia in South East of iran (zahedan). Iran J Cancer Prev. 2012; 5(3): 130-7[PubMed]
  • 14. Gokbuget N. How I treat older patients with ALL. Blood. 2013; 122(8): 1366-75[DOI][PubMed]
  • 15. Thomas X, Danaila C, Le QH, Sebban C, Troncy J, Charrin C, et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia. 2001; 15(12): 1811-22[PubMed]
  • 16. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004; 22(20): 4075-86[DOI][PubMed]
  • 17. Marcus RE, Catovsky D, Johnson SA, Gregory WM, Talavera JG, Goldman JM, et al. Adult acute lymphoblastic leukaemia: a study of prognostic features and response to treatment over a ten year period. Br J Cancer. 1986; 53(2): 175-80[PubMed]
  • 18. Ayremlou P, Razavi SM, Solaymani-Dodaran M, Vakili M, Asadi-Lari M. Demographic and prognostic factors of 455 patients with acute leukemia admitted to two referral hospitals in tehran-iran during ten years (2001-2011). Iran J Cancer Prev. 2012; 5(3): 157-63[PubMed]
  • 19. Mandhaniya S, Swaroop C, Thulkar S, Vishnubhatla S, Kabra SK, Xess I, et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. J Pediatr Hematol Oncol. 2011; 33(8)-41[DOI][PubMed]
  • 20. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997; 90(12): 4710-8[PubMed]
  • 21. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001; 322(7286): 579-82[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments